HC Wainwright Weighs in on Genprex, Inc.’s FY2023 Earnings (NASDAQ:GNPX)

Genprex, Inc. (NASDAQ:GNPX) – Equities research analysts at HC Wainwright issued their FY2023 EPS estimates for Genprex in a research note issued on Monday, March 25th. HC Wainwright analyst Y. Chen anticipates that the company will earn ($24.10) per share for the year. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Genprex’s current full-year earnings is ($21.85) per share. HC Wainwright also issued estimates for Genprex’s Q4 2023 earnings at ($5.39) EPS, Q1 2024 earnings at ($3.37) EPS, Q2 2024 earnings at ($1.60) EPS, Q3 2024 earnings at ($1.18) EPS, Q4 2024 earnings at ($1.03) EPS and FY2024 earnings at ($5.85) EPS.

Genprex Price Performance

NASDAQ:GNPX opened at $2.98 on Wednesday. Genprex has a 1-year low of $2.50 and a 1-year high of $46.00. The firm’s fifty day moving average price is $5.21 and its 200 day moving average price is $9.27. The firm has a market cap of $4.44 million, a price-to-earnings ratio of -0.12 and a beta of -0.57.

Institutional Investors Weigh In On Genprex

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new position in shares of Genprex during the 3rd quarter worth $28,000. Tower Research Capital LLC TRC raised its stake in shares of Genprex by 1,073.7% during the 3rd quarter. Tower Research Capital LLC TRC now owns 20,986 shares of the company’s stock worth $30,000 after buying an additional 19,198 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Genprex during the 2nd quarter worth $38,000. Virtu Financial LLC raised its stake in shares of Genprex by 43.9% during the 2nd quarter. Virtu Financial LLC now owns 29,710 shares of the company’s stock worth $41,000 after buying an additional 9,069 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of Genprex during the 1st quarter worth $68,000. Institutional investors and hedge funds own 14.05% of the company’s stock.

About Genprex

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes.